ClinicalTrials.gg
CompletedNCT07093398Updated Mar 25, 2026

A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants

A Phase 1 interventional study of D3S-001 in Healthy Adult Volunteers, sponsored by D3 Bio (Wuxi) Co., Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by D3 Bio (Wuxi) Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to Assess the Effect of Food on the

Pharmacokinetics (PK) of D3S-001 in Healthy Adult Participants. The main question[s] it aims to answer are:

  1. Evaluate the PK of D3S-001 administered in the fasted and fed state in healthy adult participants.
  2. Evaluate the safety and tolerability of D3S-001 administered in the fasted and fed state in healthy adult participants.

Potential participants will be screened within 28 days prior to the first dose. Participants will be admitted into the clinical research unit (CRU) on Day -1 and will be confined until end of study (EOS) or until early termination. On Day 1, participants will be randomised to Group 1 or Group 2. Participants will receive Treatment A or Treatment B in each of 2 periods (Periods 1 and 2; Study Days 1 and 4), once under fasted conditions (Treatment A) and once under fed conditions (Treatment B). Each participant will receive both treatments.

02

Conditions studied

  • Healthy Adult Volunteers

Keywords

  • D3S-001
  • D3S-001-CP003
  • Phase 1
  • Effect of Food
  • Healthy Adult Participants
03

In context

Lead sponsor

D3 Bio (Wuxi) Co., Ltd is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions.
  • Males or females of any race, aged between 18 to 65 years, inclusive, with a between 18.0 and 32.0 kg/m2, inclusive.
  • In good health, determined by no findings.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder.
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance.
  • History of stomach or intestinal surgery (including but not limited to cholecystectomy) or resection that would potentially alter absorption and/or excretion of orally administered drugs.
  • Unable or unwilling to consume the protocol-specified high-fat breakfast.

Other protocol inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Group 1 - Fasted and Fed

    Period 1 (day 1-3): Treatment A - 600mg D3S-001, following an overnight fast of at least 10 hours. Period 2 (day 4 to 6): Treatment B - 600mg D3S-001, administered 30 minutes after the start of a high-fat/high-calorie meal breakfast.

    Drug: D3S-001

  • Experimental
    Group 2 - Fed and Fasted

    Period 1 (day 1-3): Treatment B - 600mg D3S-001, administered 30 minutes after the start of a high-fat/high-calorie meal breakfast. Period 2 (day 4-6): Treatment A - 600mg D3S-001, following an overnight fast of at least 10 hours.

    Drug: D3S-001

Interventions

  • DrugD3S-001

    The investigational product dose: 600 mg D3S-001 capsules. A 600-mg oral dose of D3S-001 will be given to potential participants on Day 1 and Day 4.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax)

    Maximum Observed Concentration (Cmax) of D3S-001 administered in the fasted and fed state.

    Time frame: From screening to end of treatment at 34 days

  2. Area under the concentration-time curve

    Evaluate the area under the concentration-time curve from time zero to the time of the last quantifiable concentration after D3S-001 administered in the fasted and fed state.

    Time frame: From screening to end of treatment at 34 days

Secondary outcomes

  1. Adverse events

    Subjects will be observed for any signs or symptoms of adverse events and asked about their condition by open questioning, such as "How have you been feeling since you were last asked?", at least once each day while resident at the study site and at each study visit.

    Time frame: From screening to end of study (approximately 34 days)

  2. Number of clinically significant clinical laboratory findings

    Evaluate the safety and tolerability of the drug through clinical laboratory assessments, including clinical chemistry, haematology, coagulation, and urinalysis.

    Time frame: On Screening visit, Day -1, Days 2-3 and Days 5-6 (End of Study)

  3. Number of clinically significant electrocardiogram parameters

    Evaluate the safety and tolerability of the drug using resting 12-lead electrocardiogram (ECG) parameters, recorded after the subject has been supine and at rest for at least 5 minutes. The following ECG Measurements will be recorded: Heart Rate, RR Interval, PR Internal, QRSD QT Interval, QTcB and QTcF.

    Time frame: On screening day, Day -1 and Days 1-6 (End of Study)

  4. To determine the safety and tolerability of the drug in healthy subjects, as assessed by the collection of vital signs.

    Temperature in Degrees Celsius (℃)

    Time frame: On screening day, Day -1 and Days 1-6 (End of Study)

  5. To determine the safety and tolerability of the drug in healthy subjects, as assessed by the collection of vital signs.

    Pulse in beats per minute (bpm)

    Time frame: On screening day, Day -1 and Days 1-6 (End of Study)

  6. To determine the safety and tolerability of the drug in healthy subjects, as assessed by the collection of vital signs.

    Respiratory Rate in respirations per minute (rpm)

    Time frame: On screening day, Day -1 and Days 1-6 (End of Study)

  7. To determine the safety and tolerability of the drug in healthy subjects, as assessed by the collection of vital signs.

    Systolic and Diastolic Blood Pressure in millimeters of mercury (mmHg)

    Time frame: On screening day, Day -1 and Days 1-6 (End of Study)

  8. Number of clinically significant physical examinations

    Evaluate the safety and tolerability of the drug by performing HEENT \[head, eyes, ears, nose, and throat\], mouth/dental, neck \[including thyroid \& nodes\], cardiovascular, respiratory, gastrointestinal, renal, neurological, musculoskeletal, skin, and other examinations.

    Time frame: On Screening visit, Day -1 and Day 6 (End of Study)

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Nov 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Jul 30, 2025
StartActual
Jul 11, 2025
Primary completionActual
Nov 12, 2025
CompletionActual
Nov 17, 2025
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07093398
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Jul 11, 2025
Primary completion
Nov 12, 2025
Completion
Nov 17, 2025
Last update
Mar 25, 2026

Study contacts

Thomas Polasek, MD
principal investigator · CMAX Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion